Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome
Yucai Wang(Mayo Clinic), Wei Ding(Mayo Clinic), Haidong Dong(Mayo Clinic in Arizona), Charla Secreto(Mayo Clinic in Arizona), Timothy G. Call(Mayo Clinic), Saad S. Kenderian(Mayo Clinic in Arizona), Amber B. Koehler(Mayo Clinic in Arizona), Daniel L. Van Dyke(Mayo Clinic), Susan L. Slager(Mayo Clinic), Eli Muchtar(Mayo Clinic), Rong He(Mayo Clinic), Karen L. Rech(Mayo Clinic in Arizona), Sutapa Sinha(WinnMed), Suzanne R. Hayman, José F. Leis(Mayo Clinic), Neil E. Kay(Mayo Clinic), Linda Wellik(Mayo Clinic in Arizona), Sameer A. Parikh(Mayo Clinic)
Cited by 29
Related Papers
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735
Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis
|Antimicrobial Agents and Chemotherapy|2010|727